Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections-3

<p><b>Copyright information:</b></p><p>Taken from "Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections"</p><p>BMC Cancer 2005;5():148-148.</p><p>Published online 17 Nov 2005</p><p>PMCID:PMC1318463.</p><p>Copyright © 2005 Dambaki et al; licensee BioMed Central Ltd.</p

Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections-0

<p><b>Copyright information:</b></p><p>Taken from "Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections"</p><p>BMC Cancer 2005;5():148-148.</p><p>Published online 17 Nov 2005</p><p>PMCID:PMC1318463.</p><p>Copyright © 2005 Dambaki et al; licensee BioMed Central Ltd.</p>incubation (upper panel) or in presence of cyproterone acetate and in absence of BSA (lower panel). As explained in the text, BSA preincubation decreases or eliminates non-specific interactions of the tracer (testosterone-BSA-FITC) with prostate stroma or cell membranes, while the antiandrogen cyproterone acetate binds selectively to iAR

Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections-1

<p><b>Copyright information:</b></p><p>Taken from "Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections"</p><p>BMC Cancer 2005;5():148-148.</p><p>Published online 17 Nov 2005</p><p>PMCID:PMC1318463.</p><p>Copyright © 2005 Dambaki et al; licensee BioMed Central Ltd.</p>staining, while right panels present staining with testosterone-BSA-FITC. Note the membrane localization of fluorescence in positive cells. Lower panel presents a higher magnification of the square region shown. In all cases preincubation with 3% BSA and 10M cyproterone acetate was performed, prior to mAR detection. Compare Figure 2 with Figure 1 (no preincubation)

Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections-2

<p><b>Copyright information:</b></p><p>Taken from "Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: Study in paraffin tissue sections"</p><p>BMC Cancer 2005;5():148-148.</p><p>Published online 17 Nov 2005</p><p>PMCID:PMC1318463.</p><p>Copyright © 2005 Dambaki et al; licensee BioMed Central Ltd.</p> (n = 106) showed mAR expression in a significant percentage (38% of these cases were positive) (χ= 16.7, p < 0.0001)